<DOC>
	<DOC>NCT00836043</DOC>
	<brief_summary>This study will collect data on safety, effectiveness and patient acceptance of MabCampath treatment under daily life conditions.</brief_summary>
	<brief_title>Safety, Effectiveness and Patient Acceptance of the Treatment With MabCampath in Chronic Lymphocytic Leukemia</brief_title>
	<detailed_description>As of 29 May 2009, the clinical trial sponsor is Genzyme Corporation. NOTE: This study was originally posted by sponsor Schering AG, Germany, which was subsequently renamed to Bayer Schering Pharma AG, Germany.</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia, Lymphoid</mesh_term>
	<mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
	<mesh_term>Alemtuzumab</mesh_term>
	<criteria>In and outpatients suffering from CLL, who are treated with Mab Campath, and are routinely monitored with PCR (Polymerase Chain Reaction) for CMV infection during MabCampath treatment and for at least 2 months following completion of treatment. In accordance with Summaries of Product Characteristics (SPC).</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>CLL</keyword>
	<keyword>alemtuzumab</keyword>
</DOC>